Nineteen phenoxypyridinecarbonitriles were initially evaluated for their in vitro activity against rhinoviruses (RV) 1A, 2, and 64 and coxsackievirus (Cox) A21 and for their oral prophylactic and therapeutic activity in Swiss albino mice challenged with Cox A21. On the basis of the results of these studies, one compound, 6-(3,4-dichlorophenoxy)-3-(ethylthio)-2-pyridinecarbonitrile, was selected for further evaluation. Expanded in vitro spectrum of activity studies showed that the MIC causing a 50% reduction in viral cytopathic effect in infected cultures (MIC50) was 3.0 ,ug/ml or less against 11 of 20 RV serotypes tested. The compound was only moderately active (MIC50, 5 to 7 ,ug/ml) against four of the RV serotypes evaluated, while RV 4, 5, 8, 13 and Hank's were relatively resistant to compound inhibition. Of the nine enteroviruses studied, only Cox A21, echovirus 12, poliovirus 2, and enterovirus 70 were inhibited at compound concentrations of less than 2.0 ,ug/ml. The compound provided significant protection to mice infected with a normally lethal dose of Cox A21 when administered in a single oral dose of 150 mg/kg (P < 0.01) and during a regimen of continuous oral doses of 37.5 mg/kg per day (P < 0.001). Mechanism of action studies indicated that the compound inhibited picornavirus uncoating or some earlier virus-host cell-associated event.
of dimethyl sulfoxide (Aldrich Chemical Co., Inc., Milwaukee, Wis.) followed by the addition of 10 ml of maintenance medium to give a stock concentration of 200 ,ug of compound per ml. Dilutions were then prepared in the same medium to give test concentrations of 0.01 to 25 ,ug of compound per ml. Cell cultures in the 24-well microtiter plates were drained and refed with 1.0 ml of compound-containing or compoundfree maintenance medium. Appropriate monolayers (except compound toxicity and cell controls) were then challenged with 0.1 ml (10 to 100 50% tissue culture infective doses
[TCID50s]) of virus. Cell cultures were maintained at 33 or 36°C in a humidified CO2 incubator and examined microscopically at 48, 72 and 96 h after challenge for compound cytotoxicity and virus CPE. The lowest concentration of a compound that reduced virus CPE by 50% or more was considered to be the MIC50. A standard control compound, 6-(4-nitrophenoxy)-3-pyridinecarbonitrile, was included in each assay. During the period of phenoxypyridinecarbonitrile evaluation, control compound MIC50s of 3.1 to 6.3 ,ug/ml were obtained for RV 1A, 2 and 64 while MIC50s of 1.6 to 3.1 ,ug/ml were obtained for Cox A21.
Virus plaque reduction assay. For virus plaque reduction, monolayers of HeLa cells in 6-well microtiter plates (Becton Dickinson Labware, Oxnard, Calif.) were inoculated with 0.1 ml of virus in maintenance medium. Cell controls received 0.1 ml of maintenance medium. All cultures were incubated for 90 min at 36°C in a humidified CO2 incubator to allow for virus adsorption. Each monolayer was then overlaid with 2 ml of a medium composed of 87% (vol/vol) McCoy 5a medium supplemented with 2% HIFCS, 50 jig of penicillin and streptomycin per ml, 100 jig of neomycin per ml, 10% of a 3.5% ion agar solution, 2% of a 1.5 M solution of MgCl2 6H20, and 1% of a 0.2% dextran solution (DEAEdextran, molecular weight, 2 x 106; Pharmacia, Uppsala, Sweden). Selected concentrations of the compound were incorporated into the overlay medium before it was layered over the virus-inoculated cell monolayer. After incubation for 48 to 72 h at 36°C in a humidified 5% CO2 atmosphere, the overlay medium was removed by inverting the plate. At this time, each cell layer was fixed and stained with 1 to 2 ml of 0.1% crystal violet (Allied Chemical, New York, N.Y.) in ethanol-water (20:80). After approximately 5 min, the dye was removed by gentle rinsing with water, the plates were allowed to dry, and the plaques were counted.
Determination of biologically active compound levels in mouse serum. For the serum assay, HeLa cell monolayers in 24-well microtiter plates were drained, and the cultures were refed with 1.0 ml of twofold serial dilutions of mouse serum in maintenance medium. After 2 h at 36°C the test cultures were challenged with 0.05 ml (30 TCID50s) Cox A21 in maintenance medium. Compound control cultures containing 0.13 to 2.0 jig of compound per ml of maintenance medium were similarly challenged. Cell (1.0 ml of maintenance medium) and virus (1.0 ml of maintenance medium plus 0.05 ml of challenge virus) control Mechanism of action. The effects of a test compound on cellular and viral RNA synthesis, virus uncoating, and direct virus inactivation were determined by the methods described in an earlier report from this laboratory (9) . Briefly, leased after uncoating is unaffected. To determine whether Mitomycin C was used as a positive control at concentrathe antiviral activity of a compound was related to direct tions of 1.25 to 10 ,ug/ml. At 16 to 17 h later, an equal volume inactivation of the virus, RV 1A was incubated at 40 to 41°C of 10% trichloroacetic acid was added to each culture, and for 4 h in either the presence or absence of 2 jig of test agent the cells were processed as described previously (9) . The per ml. After incubation, infectivity titers of the two prepaeffects of test compound on cellular protein synthesis were rations were determined by adding 0.1-ml volumes of 10-fold measured indirectly by determining the incorporation of a serial dilutions of the two viral preparations to HeLa cells in L-[U-14C]amino acid mixture (>50 mCi/mg-atom of C; 24-well tissue culture plates. Six wells were used for each Amersham) into a trichloroacetic acid-insoluble fraction of dilution. At 5 days after inoculation, the wells were scored the cells. At 2 after initial exposure of HeLa cells to medium with or without test compound, 0.2 ,uCi of "4C-amino acids was added to each culture. At 8 h later the cells were processed as described previously (9) . Cycloheximide (100 ,ug/ml) was used as positive control for protein synthesis studies. RESULTS In the initial search for agents active against picomaviruses, 19 phenoxypyridinecarbonitriles were evaluated for were most active against RV 64. In general, the phenoxypyridinecarbonitriles described were highly active against Cox A21. Only compounds 1, 10, 12, 14, and 16 had MIC50s greater than 1.6 ,ug/ml.
Initial evaluation of the phenoxypyridinecarbonitriles showed that compound 16 was cytotoxic for HeLa cells at 25 ,ug/ml, compound 5 was cytotoxic at 12.5 ,ug/ml (Tables 1  and 2 ). The remaining compounds were not cytotoxic to HeLa cells at concentrations of up to 25 ,ug/ml.
Of the 18 phenoxypyridinecarbonitriles evaluated in the single-oral-dose test, compounds 4, 5, 6, 8, 11, 12, 13, 14, and 17 showed significant protective activity (Table 3) , compounds 4, 6, and 11 being the most active. Of the 13 phenoxypyridinecarbonitriles evaluated in the continuous drug diet test, compound 4 was the only agent displaying significant (P < 0.02) activity (Table 3) .
These initial findings led to expanded studies of the activities of compound 4 [6-(3,4-dichlorophenoxy)-3-(ethylthio)-2-pyridinecarbonitrile]. The MIC50 of this compound was equal to or less than 3.0 ,ug/ for 11 of the 20 (55%) RV serotypes ( Table 4 ). The MIC50 was 5 to 7 ,ug/ml for 4 (20%) of the RV serotypes, and it was significantly less active against RV 4, 5, 8, 13 , and Hank's. Of the enteroviruses evaluated, only Cox A21, echovirus 12, poliovirus 2, and enterovirus 70 were inhibited at concentrations of less than 2.0 jig/ml. Cox A7, B3, and B4 and enterovirus 71 were only moderately susceptible or were resistant to compound activity.
In vivo dose-response studies (Table 5) showed compound 4 to be significantly (P < 0.01) active in the single-oral-dose (4) showed that A21.
neutral red incorporation by picornaviruses during replicaThese in vivo protective endpoints appeared to be high in tion renders the progeny virions sensitive to light until the relation to the exquisite in vitro activity of compound 4 neutral red is lost after virus uncoating. Preliminary experiagainst Cox A21 (MIC50, 0.01 p.g/ml), suggesting problems ments (data not shown) in our laboratory involving exposure with absorption from the gastrointestinal tract or distribution of neutral red-sensitized Cox A21 to light at various times to virus target tissues. As a result, a series of preliminary after infection of HeLa cells showed that the virus is light studies was initiated to investigate this phenomenon. Peak sensitive and that 59 to 80% of the virions lose light sensilevels of 4.8 ,ug (480x MIC50 for Cox A21) of biologically tivity (uncoat) 3 to 4 h after infection. active compound per ml were observed in the sera of mice Table 6 summarizes the effects of compound 4 on the 1.5 to 3.0 h after a single oral dose of 500 mg of compound 4 uncoating of photosensitized Cox A21. In these studies, per kg either suspended in Methocel or dissolved in polyethHeLa cells were challenged with approximately 200 PFU of ylene glycol 400. In addition, after 3 h, levels of 4.8 xg of Cox A21 in the presence or absence of 2 ,ug of compound 4 biologically active compound per ml were observed in the per ml. One set of cultures was exposed to light within 5 to sera of mice receiving a single oral dose of 500 mg of 10 min after addition of virus (conditions A and B). A second compound 4 per kg 1 h after i.p. treatment with 0 or 10 mg of set was exposed to light 3 h after virus challenge (conditions the hepatic metabolism blocker Proadifen hydrochloride C and D), and a third set received no light exposure (Smith Kline & French 525A) per kg. Finally, in a compar-(conditions E, F, and G). All monolayers except the comative single-oral-dose test with 30 mice per test group, it was pound controls (condition G) were thoroughly washed 3 h found that the survival of animals receiving a normally lethal after virus challenge, agar overlay was added, and the Cox A21 challenge and 200 mg of compound 4 (suspended in plaques were allowed to develop. The photosensitivity of the Methocel) per kg was significantly (P < 0.05) increased if the Cox A21 used in these experiments was exhibited by the lack compound was given i.p. rather than by the oral route.
of plaque formation in those cultures for which light expoMechanism of action studies showed that compound 4 ,ug/ml, growth of isolated HeLa cell colonies was inhibited discernibly at 12.5 pug/ml. Mechanism of action studies ( Fig.   1 ) showed that this agent had little effect on cellular RNA or protein synthesis, but inhibited cellular DNA synthesis by 13 and 23% at concentrations of 12.5 and 25.0 ,ug/ml, respectively.
DISCUSSION
Earlier studies (7, 9) have shown that the phenoxybenzene 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile has significant activity against a spectrum of picornaviruses when applied in concentrations of 1.5 p.g/ml or less in the CPE inhibition assay (9) . In addition, logl0 yields of progeny virions are reduced by >1 at 1.0 ,ug of compound per ml with 72 or 90 (80%) RV strains and 8 of 10 (80%) enterovirus strains studied (7) . The results of the current study show that in vitro antipicornavirus activity is not improved by replacement of one of the benzene rings with analogs containing an electron-deficient pyridine ring substituted with an electronwithdrawing cyano group and a sulfur-containing alkyl moiety. Of these derivatives, compound 4 [6-(3,4-dichlorophenoxy)-3-(ethylthio)-2-pyridinecarbonitrileJ exhibits the best in vitro and in vivo antipicornavirus activity. However, protective endpoints obtained in the Cox A21 challenge studies appear to be high in relation to the exquisite in vitro activity of the compound against Cox A21. Preliminary pharmacological studies show that levels of biologically active compound in blood are the same whether the compound is administered as an oral dose either suspended in Methocel or dissolved in polyethylene glycol 400, showing that dissolution has little effect on systemic bioavailability.
In addition, pretreatment of mice with the hepatic metabolism (mixed function oxidases) blocker Proadifin hydrochloride also has no noticeable effect on the levels of active compound in blood, suggesting that compound 4 does not undergo extensive first-pass metabolism to an inactive species. Finally, the increased in vivo protective efficacy of compound 4 given i.p. when compared with oral administration is indicative of problems with absorption from the gastrointestinal tract. At present, nothing is known of tissue distribution and elimination profiles or the metabolism of the phenoxypyridinecarbonitriles in mice. Studies by Lerner et al. (3) in adult mice showed virus levels of 4.0 log10 TCID50 per ml and 1.6 to 2.0 log1o TCID50 per g in blood and muscle, respectively, within 1 day of i.p. challenge with Cox A9.
These studies also showed that a viremic phase preceded tissue involvement. Our studies have shown that compound 4 does not directly inactivate picornaviruses and would therefore be expected to have no effect on the viremic phase of the infection. However, since compound 4 affects some early event in the picornavirus replicative cycle, deposition of the compound or its active metabolites in target tissues is extremely important. Pharmacokinetic studies are needed to clarify these points.
